MMS · Q4 2026 results

Maximus, Inc. Q4 2026 Earnings Recap

Published November 20, 2026 MMS -5.0% after the report

Maximus shares fell 5.0% after earnings, with investors likely focused on management’s warning that elevated fourth-quarter clinical volumes will moderate and on the absence of fiscal 2027 guidance in the available remarks. Full-year margin and EPS improved, but those positives may not offset uncertainty about the durability of recent performance.

The numbers

Reported results against what analysts expected.

Earnings per share $2.11 vs $1.85 expected · beat by 14.1%
Revenue 1300808000 vs 1296673000 expected · beat by 0.3%
Stock after the report -5.00% close to close around the results

Key takeaways

From the Q4 2026 earnings call.

  • Fiscal 2026 adjusted EBITDA margin rose to 14.2% from 12.9% in fiscal 2025; management said the year began with an outlook of approximately 13.7%.
  • Adjusted EPS increased to $8.24 from $7.36 a year earlier.
  • Management said higher clinical volumes contributed to fourth-quarter results and are expected to moderate; it also cited a pause in VA MDE incentives in the quarter.
  • Maximus returned $192 million through share repurchases in fiscal 2026 and said its Agile Defense acquisition has closed, with integration underway.
  • Agile Defense reported year-to-date book-to-bill of approximately 3.1x; Maximus expects double-digit organic growth in calendar 2027 on roughly $450 million of revenue.
Your portfolio

Track earnings for the stocks you own

Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.

Also published on November 20, 2026

This summary was written by AI from the official earnings call transcript. It is for information only and is not financial advice. For MMS's price history and fundamentals, see the MMS stock page.